How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

7 results for

Non-Sulfonylurea Insulin Secretagogues

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Non-Sulfonylurea Insulin Secretagogues

Non-Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Non (...) -Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Aka: Non-Sulfonylurea Insulin Secretagogues , Meglitinide , Repaglinide , Prandin , Nateglinide , Starlix From Related Chapters II. Mechanism secretogogue III. Indication Early Oral Agent Elevated postprandial Consider if only used intermittently pre-meal IV. Contraindications to sulfa V. Category VI. Mechanism Benzoic acid derivative Similar to Binds different sites from s Closes ATP sensitive K+ channels Results in secretion

2018 FP Notebook

2. Non-Sulfonylurea Insulin Secretagogues

Non-Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Non (...) -Sulfonylurea Insulin Secretagogues Non-Sulfonylurea Insulin Secretagogues Aka: Non-Sulfonylurea Insulin Secretagogues , Meglitinide , Repaglinide , Prandin , Nateglinide , Starlix From Related Chapters II. Mechanism secretogogue III. Indication Early Oral Agent Elevated postprandial Consider if only used intermittently pre-meal IV. Contraindications to sulfa V. Category VI. Mechanism Benzoic acid derivative Similar to Binds different sites from s Closes ATP sensitive K+ channels Results in secretion

2015 FP Notebook

3. Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes

-liraglutide to reference liraglutide. Condition or disease Intervention/treatment Phase Diabetes Mellitus, Type 2 Drug: Liraglutide 6 MG/ML Pen Injector Drug: Metformin Drug: Sulfonylurea/non-sulfonylurea insulin secretagogues Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 300 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary (...) -sulfonylurea insulin secretagogues with maximum tolerable dose. Drug: Liraglutide 6 MG/ML Pen Injector Patients in each arm will receive either CinnaGen-liraglutide or Victoza®. Both products will be provided as pen-injector. Other Name: CinnaGen-liraglutide, Victoza Drug: Metformin Patients who were receiving metformin with maximum tolerable dose prior to study will continue to receive it during the study. Other Name: Metformin Hydrochloride Drug: Sulfonylurea/non-sulfonylurea insulin secretagogues

2018 Clinical Trials

4. A Retrospective Cohort Study of Acute Pancreatitis in Relation to Use of Exenatide and Other Antidiabetic Agents

: exenatide subcutaneous injection, dosing according to normal clinical practice Other Name: Byetta Other Antidiabetic Drug Initiators Drug: Other antidiabetic therapies Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice Non-Diabetes Cohort Other: No diabetes therapy Subjects not diagnosed with diabetes Outcome Measures Go to Primary Outcome Measures (...) to the extent necessary to ensure inclusion of at least as many persons initiating these drugs as initiating exenatide. Specifically, oversampling will be performed as needed on initiators of metformin, TZDs, SUs, sitagliptin and insulin glargine to allow for further sub-analysis. Exenatide and Other Antidiabetic Drug Initiators: For all patients in these two study cohorts, the date of cohort entry (the date ranged between January 1, 2005 and December 31, 2007) marked the beginning of observation for study

2010 Clinical Trials

5. Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes

anti-diabetic agents which are non-insulin secretatgogues, i.e. Metformin and/or Pioglitazone Able to give informed consent Expected to be in the DC metropolitan for the duration of the study Fasting blood glucose between 70 and 250 mg/dl Exclusion Criteria: Patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (Symlin), GLP-1 analogs (Byetta), insulin, or alpha-glycosidase inhibitors A1c under 7.0% or over 10.0% Fasting blood (...) with type 2 diabetes mellitus and relate these responses to one of the two well-recognized indices of insulin sensitivity - HOMA-R and QUICKI. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 19 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Official Title: Assessment of Glycemic Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes Mellitus Study Start Date : May 2006

2009 Clinical Trials

6. Pioglitazone for the Treatment of Major Depressive Disorder Comorbid With Metabolic Syndrome

suicidal risk as judged by the investigator or having a score > 2 on item 18 of the Inventory of Depressive Symptomatology-Clinician Rated (IDS-CR) scale Known history of intolerance or hypersensitivity to pioglitazone Treatment with pioglitazone in the 3 months prior to randomization Currently taking an antidiabetic/glucose-lowering agent. Antidiabetic agents that are prohibited include insulin, rosiglitazone, metformin, sitagliptin, sulfonylureas (e.g. glyburide, glipizide, glimepiride), non (...) -sulfonylurea secretagogues (e.g. repaglinide, nateglinide), incretins (e.g. exenatide), and α-glucosidase inhibitors (e.g. acarbose, miglitol). Diagnosed with dementia Diagnosed with heart failure Transaminase elevation >2.5 times the upper limit of normal Presence of renal impairment Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor

2008 Clinical Trials

7. Clinical inquiries. What is the best medical therapy for new-onset type 2 diabetes? (Abstract)

Clinical inquiries. What is the best medical therapy for new-onset type 2 diabetes? Sulfonylureas, metformin, thiazolidinediones, and non-sulfonylurea secretagogues differ little in their ability to decrease glycosylated hemoglobin (Hb A1c) levels when used as initial monotherapy for diabetes mellitus type 2 (strength of recommendation [SOR]: A, based on systematic reviews); alpha-glucosidase inhibitors may also be as effective (SOR: B, based on systematic reviews with inconsistent results (...) ). Metformin is generally indicated in obese patients because it improves all-cause mortality and diabetes related outcomes (SOR: B, based on a single high-quality randomized controlled trial [RCT]). Insulin is generally not recommended as an initial agent (SOR: C, expert opinion).

2006 Journal of Family Practice

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>